Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Canadian scientist develops world's most advanced drug to protect the brain after a stroke

01.03.2012
Scientists at the Toronto Western Research Institute (TWRI), Krembil Neuroscience Center, have developed a drug that protects the brain against the damaging effects of a stroke in a lab setting. This drug has been in development for a few years.

At this point, it has reached the most advanced stage of development among drugs created to reduce the brain's vulnerability to stroke damage (termed a "neuroprotectant").

Over 1000 attempts to develop such drugs by scientists worldwide have failed to be translated to a stage where they can be used in humans, leaving a major unmet need for stroke treatment. The drug developed by the TWRI team is the first to achieve a neuroprotective effect in the complex brain of primates, in settings that simulate those of human strokes. ischemic stroke.

The study, "Treatment of Stroke with a PSD95 inhibitor in the Gyrencephalic Primate Brain", published online today in Nature, shows how the drug, called a "PSD95 inhibitor" prevents brain cell death and preserves brain function when administered after a stroke has occurred.

"We are closer to having a treatment for stroke than we have ever been before," said Dr. Michael Tymianski, TWRI Senior Scientist and the study's lead author. "Stroke is the leading cause of death and disability worldwide and we believe that we now have a way to dramatically reduce its damaging effects."

During a stroke, regions of the brain are deprived of blood and oxygen. This causes a complex sequence of chemical reactions in the brain, which can result in neurological impairment or death. The PSD95 inhibitor published by the Toronto team acts to protect the brain by preventing the occurrence of these neurotoxic reactions.

The study used cynomolgus macaques, which bear genetic, anatomic and behaviour similarities to humans, as an ideal model to determine if this therapy would be beneficial in patients.

Animals that were treated with the PSD95 inhibitor after a stroke had greatly reduced brain damage and this translated to a preservation of neurological function. These improvements were observed in several scenarios that simulated human strokes. Specifically, when the treatment was given either early, or even at 3 hours, after the stroke onset, the animals exhibited remarkable recoveries. Benefits were also observed when the drug therapy was combined with conventional therapies (aimed at re-opening blocked arteries to the brain). Beneficial effects were observed even in a time window when conventional therapies on their own no longer have an effect.

"There is hope that this new drug could be used in conjunction with other treatments, such as thrombolytic agents or other means to restore blood flow to the brain, in order to further reduce the impact of stroke on patients," said Dr. Tymianski. "These findings are extremely exciting and our next step is to confirm these results in a clinical trial."

Dr. Michael Tymianski holds a Tier 1 Canada Research Chair in Translational Stroke Research. He is a neurosurgeon at Toronto Western Hospital, the Medical Director of the Neurovascular Therapeutics Program and the Interim Head of the Division of Neurosurgery at the University Health Network. He is also a Professor in the Department of Surgery and a member of the Institute of Medical Science at the University of Toronto.

About Krembil Neuroscience Centre

The Krembil Neuroscience Centre (KNC), located at Toronto Western Hospital, is home to one of the largest combined clinical and research neurological facilities in North America. Since opening in 2001, KNC has been recognized as a world leader through its research achievements, education and exemplary patient care. The centre focuses on the advancement, detection and treatment of neurological diseases and specializes in movement disorders, dementias, stroke, spinal cord injury, blinding eye diseases, epilepsy and cancer-related conditions.

For more information please visit www.krembil.com
About University Health Network
University Health Network consists of Toronto General, Toronto Western and Princess Margaret Hospitals. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, and genomic medicine. University Health Network is a research hospital affiliated with the University of Toronto.

For more information please visit www.uhn.ca

For more information, please contact:
Nadia Daniell-Colarossi
Krembil Neuroscience Centre
Toronto Western Hospital
Tel: 416-603-5294
nadia.daniell-colarossi@uhn.on.ca

Nadia Daniell-Colarossi | EurekAlert!
Further information:
http://www.uhn.on.ca

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>